Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
03/2009
03/19/2009WO2009035368A1 Antidiabetic pharmaceutical composition
03/19/2009WO2009035070A1 Transdermally absorbable preparation and transdermally absorbable system using the same
03/19/2009WO2009034388A1 Compounds for the treatment of metabolic disorders
03/19/2009WO2009034325A1 Isoflavone formulation
03/19/2009WO2009034133A1 Polymorph forms of (s)-2-((4-benzofuranyl)carbonylaminomethyl)-1-((4-(2-methyl-5-(4-fluorophenyl)thiazolyl)carbonyl)piperidine
03/19/2009WO2009034117A1 Mixture comprising an amylin peptide and a protracted insulin
03/19/2009WO2009034110A1 Prevention of type 1 diabetes by administration of gliadin
03/19/2009WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent
03/19/2009WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent
03/19/2009WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent
03/19/2009WO2009033821A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
03/19/2009WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
03/19/2009WO2009033818A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent
03/19/2009WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
03/19/2009WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent
03/19/2009WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
03/19/2009WO2009033813A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent
03/19/2009WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof
03/19/2009WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection
03/19/2009WO2009033809A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033808A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033807A2 Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
03/19/2009WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent
03/19/2009WO2009033805A2 Use of somatostatin-14 as a therapeutic agent
03/19/2009WO2009033804A2 Use of gamma- endorphin as a therapeutic agent
03/19/2009WO2009033803A2 Use of the pentapeptide drlds and gamma-endorphin as therapeutic agents
03/19/2009WO2009033802A2 Antide as a therapeutic agent
03/19/2009WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent
03/19/2009WO2009033800A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033799A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent
03/19/2009WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection
03/19/2009WO2009033796A1 Use of a peptide as a therapeutic agent
03/19/2009WO2009033795A2 Use of a obestatin as a therapeutic agent
03/19/2009WO2009033794A2 Use of endothelin-1, optionally in combination with obestatin, as a therapeutic agent
03/19/2009WO2009033793A2 Pentagastrin as a therapeutic agent
03/19/2009WO2009033792A2 Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
03/19/2009WO2009033791A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033790A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033789A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033788A2 Use of a jck-301, optionally in combination with big endothelin, as a therapeutic agent.
03/19/2009WO2009033787A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033786A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033785A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection
03/19/2009WO2009033784A2 Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection
03/19/2009WO2009033783A2 Use of carbetocin to treat of eg aids or idiopathic pulmonary fibrosis
03/19/2009WO2009033782A2 Use of a teprotide and optionally carbetocin to treat eg aids or idiopathic pulmonay fibrosis
03/19/2009WO2009033781A2 Use of k237 as therapeutic agent
03/19/2009WO2009033780A2 Use of growth hormone-releasing factor and/or k237 as a therapeutic agents
03/19/2009WO2009033778A2 Mage-3 antigen and others for use as a therapeutic agent
03/19/2009WO2009033777A1 Leuprolide analog as a therapeutic agent
03/19/2009WO2009033776A1 Use of a defensin peptide as a therapeutic agent
03/19/2009WO2009033775A2 Peptide alpmhir alone or in combination with peptide yvpfppf as therapeutic agent
03/19/2009WO2009033774A2 Use of a laminin nonapeptide as a therapeutic agent
03/19/2009WO2009033773A2 Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
03/19/2009WO2009033772A1 Use of a peptide as a therapeutic agent
03/19/2009WO2009033771A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033770A2 Calcitonin c-terminal flanking peptide for use as a therapeutic agent
03/19/2009WO2009033769A2 Use of cortistatin 14 and others as a therapeutic agent
03/19/2009WO2009033768A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033767A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033766A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033765A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033763A1 Nafarelin and carboxymethyl-phe-leu as therapeutic agents
03/19/2009WO2009033762A2 Use of endothelin-3 as a therapeutic agent
03/19/2009WO2009033761A2 Use of a fragment of hcv nucleo protein, alone or together with endothelin-3, as a therapeutic agent
03/19/2009WO2009033760A2 Use of fibronectin fragment (196-203 ) as a therapeutic agent
03/19/2009WO2009033759A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033758A2 Use of the peptide phpfhffvyk as therapeutic agent
03/19/2009WO2009033757A2 Use of mage-3 antigen (271-279) as a therapeutic agent
03/19/2009WO2009033756A2 Use of oxyntomodulin alone or in combination with melanotropin potentiating factor as a therapeutic agent
03/19/2009WO2009033755A2 Use of l-carnosine as a therapeutic agent
03/19/2009WO2009033754A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033751A2 Use of leu-enkephalin as a therapeutic agent
03/19/2009WO2009033750A2 Use of phm-27 alone or in combination with leu-enkephalin as a therapeutic agent
03/19/2009WO2009033749A2 Use of thymopentin as a therapeutic agent
03/19/2009WO2009033748A2 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent
03/19/2009WO2009033747A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033746A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033745A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033744A1 Use of urodilatin as a therapeutic agent
03/19/2009WO2009033741A2 Use of lvv-hemorphin-6 and optionally af12198 as therapeutic agent(s)
03/19/2009WO2009033740A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033739A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033738A2 Use of glucagon (1-29) alone or in combination with neuropeptide w30 as a therapeutic agent
03/19/2009WO2009033736A2 Use of met-enkephalin as a therapeutic agent
03/19/2009WO2009033735A2 Use of melanin concentrating hormone and met-enkephalin as therapeutic agents
03/19/2009WO2009033734A2 Use of a peptide as a therapeutic agent
03/19/2009WO2009033733A2 Use of apeptide as a therapeutic agent
03/19/2009WO2009033732A2 Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
03/19/2009WO2009033731A2 Use of a laminin peptide as a therapeutic agent
03/19/2009WO2009033730A2 Peptide gxgrgdspca as a therapeutic agent
03/19/2009WO2009033729A2 Therapeutic uses of gastrin- 1 and g- pen-grgdspca
03/19/2009WO2009033726A2 Use of cart (55-102), optionally in combination with tuftsin, as a therapeutic agent
03/19/2009WO2009033725A1 Use of human neuropeptide as a therapeutic agent
03/19/2009WO2009033724A1 Use of c-type natriuretic peptide, alone or incombination with neuropeptide af, as a therapeutic agent
03/19/2009WO2009033723A2 Use of aip2 as a therapeutic agent
1 ... 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 ... 1298